Status:
RECRUITING
Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborating Sponsors:
Institut de Cancérologie de la Loire
Jean Monnet University
Conditions:
Malignant Hemopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse. Hemat...
Detailed Description
Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse. Hemat...
Eligibility Criteria
Inclusion
- Adult patient, over 18 years of age, suffering from a malignant hemopathy (without exception),
- Patient for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated,
- Signed informed consent,
- Patient covered by a social security scheme.
Exclusion
- Allogeneic hematopoietic stem cell transplantation from cord blood or haplo-identical transplant,
- Allogeneic transplant with post-transplant cyclophosphamide treatment,
- Allograft with sequential conditioning.
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04517656
Start Date
May 25 2022
End Date
September 30 2026
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055